Pharmaceutical AI startup Graph AI is in talks to raise $14 million (about ₹133 crore) in a Series A funding round led by US-based Insight Partners, according to inc42.com. The round will also include participation from existing investor Bessemer Venture Partners. The discussions are ongoing and the final amount could change. This follows a $3 million seed round raised over eight months ago.
Founded in 2024 by CEO Raghav Parvataraju, CTO Vijay Ponukumati, CPO Mohan Konyala, and CFO Ashutosh Bordekar, Graph AI offers the AI-native platform Graph Safety. The platform automates adverse drug event monitoring, regulatory submissions, and safety intelligence aggregation for pharmaceutical and biotech companies. It integrates multiple pharmacovigilance functions into one connected SaaS ecosystem, built on the company’s graphx platform, according to inc42.com.
Pharmacovigilance is a critical process mandated by global drug regulators, requiring continuous monitoring and reporting of adverse drug events throughout a drug’s lifecycle. Graph AI’s platform aims to streamline this complex workflow, which includes case processing, signal detection, risk management, and compliance. The startup’s approach aligns with growing demand for AI solutions in drug safety, a sector attracting increasing investor interest, inc42.com reports.
Graph AI’s Series A round, led by Insight Partners with Bessemer Venture Partners also participating, remains under negotiation. The startup’s previous seed round of $3 million was led by Bessemer Venture Partners. No official statements have been made by the company or investors as of now, inc42.com confirms.